TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18517090
Drug: Enhanced Treatment
Normalized name: Thera-M Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment (ET)
Study: 18517090
Drug: Minimal Treatment
Normalized name: Minimally modified low density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Treatment (MT)
Study: 12757209
Drug: Proguanil 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil 100 mg BID plus sulfamethoxazole 1,000 mg BID for 7 days
Study: 7894098
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate (CP) applied twice daily for 16 days (phase 1)
Study: 1657248
Drug: Heparin or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin or low molecular weight heparin (LMWH; Fragmin)
Study: 6406438
Drug: Bupropion (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (450 to 750 mg/day)
Study: 6406438
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 to 225 mg/day)
Study: 26370148
Drug: Usual follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual follow-up treatment
Study: 21992993
Drug: 0.1% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% timolol maleate gel
Study: 21992993
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate gel
Study: 17530933
Drug: HMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (3 g.d(‐1))
Study: 17530933
Drug: HMBCr (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMBCr (12 g.d(‐1) with 3 g HMB, 3 g Cr, 6 g carbohydrates)
Study: 15061303
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine 0.5 per cent
Study: 9062158
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy and total parenteral nutrition (TPN)
Study: 9062158
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy alone
Study: 9062158
Drug: Chemotherapy (unspecified)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (unspecified)
Study: 8458110
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose duteplase (0.16-0.29 MIU/kg)
Study: 8458110
Drug: Middle dose
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle dose duteplase (0.30-0.41 MIU/kg)
Study: 8458110
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose duteplase (0.43-0.74 MIU/kg)
Study: 8458110
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of duteplase
Study: 30321689
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + 9 weekly cycles of docetaxel + 3 years of androgen deprivation therapy (arm B)
Study: 30321689
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + 3 years of luteinizing hormone-releasing hormone analogues (arm A)
Study: 27450646
Drug: Sesamin capsules;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesamin capsules; 200 mg/day
Study: 27450646
Drug: Placebo capsules;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules; 200 mg/day starch
Study: 19410978
Drug: Egg group
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg group (640 mg/d additional dietary cholesterol)
Study: 19410978
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (0 mg/d additional dietary cholesterol)
Study: 16675507
Drug: Sparkling wine
Normalized name: Wine grape
DrugBank: Wine grape (DB10634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparkling wine (30 g of ethanol/day for 28 days)
Study: 16675507
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (20 g of ethanol/day for 28 days)
Study: 16675507
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (20 g of ethanol/day for 28 days)
Study: 16675507
Drug: Gin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gin (30 g of ethanol/day for 28 days)
Study: 15138203
Drug: ALA-PDT (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (single dose of 100 J/cm² at four hours) - PDT100 (n=13)
Study: 15138203
Drug: ALA-PDT (fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (fractionated dose of 20 and 100 J/cm² at one and four hours) - PDT20+100 (n=13)
Study: 9757191
Drug: Post-operative chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative chemotherapy and pre-operative induction chemotherapy in patients with stage IIIA N2 disease
Study: 9757191
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with thoracic radiotherapy (TRT) in unresectable, locally advanced NSCLC
Study: 9757191
Drug: Timely combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely combination of TRT and chemotherapy
Study: 9757191
Drug: Chemotherapeutic agents
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agents as radiosensitizers
Study: 9757191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TRT and new agents in unresectable, locally advanced NSCLC
Study: 9757191
Drug: Cancer chemotherapy
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer chemotherapy for advanced NSCLC
Study: 9757191
Drug: Cancer chemotherapy
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer chemotherapy in metastatic NSCLC
Study: 9757191
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents (irinotecan, paclitaxel, docetaxel, vinorelbine, gemcitabine) along with combination chemotherapy
Study: 8058236
Drug: Terodiline, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terodiline, 25 mg twice daily
Study: 31583943
Drug: G‐CSF support
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF support during EC and docetaxel
Study: 31583943
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy without G‐CSF support
Study: 31583943
Drug: G‐CSF use
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF use
Study: 19623435
Drug: Trazodone (5HT2a/c
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (5HT2a/c antagonist)
Study: 15213587
Drug: Evidence-based pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based pharmacotherapy algorithm
Study: 11360134
Drug: Selenium and
Normalized name: Selenium and/or selenium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium and zinc supplementation (Se 200 microg/day and Zn 21 mg/day) for 50 days
Study: 9340698
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg daily)
Study: 8369892
Drug: Hydrotherapy (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotherapy (twice weekly for 6 weeks in addition to home exercises)
Study: 3789649
Drug: Hydrochlorothiazide (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (20-50 mg/day)
Study: 3789649
Drug: Indacrinone (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacrinone (50-100 mg/day)
Study: 3789649
Drug: Indacrinone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacrinone plus amiloride (50-100 mg and 5-10 mg/day)
Study: 30103772
Drug: C21 (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 (an angiotensin type 2 receptor agonist)
Study: 30103772
Drug: Candesartan (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (an angiotensin receptor blocker)
Study: 30103772
Drug: Saline/C21 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/C21 monotherapy
Study: 26259675
Drug: Uncoated mini-tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated mini-tablets
Study: 21147783
Drug: Rocuronium (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.3 mg kg⁻¹)
Study: 21147783
Drug: Alfentanil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (20 µg kg⁻¹)
Study: 21147783
Drug: Placebo (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (i.v. saline 0.5 ml kg⁻¹)
Study: 15018018
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg/g cream
Study: 8219654
Drug: Insulin treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin treatment; hemoglobin A1c before: 11.3 +/- 2.8, after: 7.0 +/- 1.0
Study: 8219654
Drug: Sulfonylurea treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea treatment; hemoglobin A1c before: 11.3 +/- 1.4, after: 7.3 +/- 0.9
Study: 31729108
Drug: Magnolol additive
Normalized name: magnolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnolol additive (MA) at 100, 200, and 300 mg/kg for 3 weeks
Study: 31729108
Drug: Colistin sulphate
Normalized name: Colistin sulphate
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistin sulphate (CS) at 30 mg/kg for 3 weeks
Study: 23908141
Drug: MCPH1-2550-CC genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCPH1-2550-CC genotype with 10-27 pack-years of smoking
Study: 21918956
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (two cycles of cisplatin and 5-fluorouracil)
Study: 21918956
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (two cycles of cisplatin and 5-fluorouracil)
Study: 10507591
Drug: Intravenous antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antihistamines (diphenhydramine, 1 mg/kg, and cimetidine, 4 mg/kg)
Study: 4028748
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of dipyridamole for 24 hours
Study: 4028748
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 100 mg of aspirin daily
Study: 28176386
Drug: Intensive bisphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive bisphosphonate therapy (zoledronic acid)
Study: 23538648
Drug: Food preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food preparation dependence
Study: 21147262
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g/day for ≥1 month)
Study: 12601676
Drug: Single-dose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration of Hypericum extract LI 160 (6 or 12 coated tablets, 5400 or 10800 microgram hypericin)
Study: 12601676
Drug: Steady-state administration
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady-state administration of Hypericum extract LI 160 (initial dose of 6 tablets, 5400 microgram hypericin, followed by 3 x 1 tablets, 2700 microgram hypericin per day for 7 days)
Study: 9122747
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) followed by autologous bone marrow transplantation
Study: 26313157
Drug: MNTX-ER (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNTX-ER (500 mg)
Study: 26313157
Drug: MNTX-SC (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNTX-SC (12 mg)
Study: 26313157
Drug: MNTX-IR (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNTX-IR (500 mg)
Study: 24980265
Drug: Live saxophone
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live saxophone music therapy (30 minutes)
Study: 7749445
Drug: Continuous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lateral rotation therapy
Study: 17999977
Drug: Atazanavir (49
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (49 on 400 mg once daily, and 53 on 300 mg plus 100 mg of ritonavir once daily)
Study: 10716102
Drug: Methadone in
Normalized name: methadone Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone in decreasing doses (10 days)
Study: 9213861
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg/12 hourly)
Study: 9213861
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms/12 hourly)
Study: 2996747
Drug: Intensive chemo‐radio‐immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemo‐radio‐immunotherapy regimen with cyclophosphamide, doxorubicin, vincristine, VP‐16, and cisplatin, followed by prophylactic whole‐brain radiotherapy and multifield radiotherapy.
Study: 31605550
Drug: M. bovoculi
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. bovoculi vaccine (2 doses)
Study: 25719429
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride (1500 mg/d) plus chondroitin sulfate (1200 mg/d) for 28 days
Study: 25195813
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT, DAT plus cilostazol)
Study: 21345843
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT) in carriers of CYP2C19 LOF allele
Study: 21345843
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT) in carriers of CYP2C19 LOF allele
Study: 21345843
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT) in non-carriers of CYP2C19 LOF allele
Study: 16484290
Drug: Iloprost treatment
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost treatment (intravenous infusion at progressively increasing doses from 0.5 to 2 ng/kg/min for 6 hours each day for 10 days, repeated every 3 months for 18 months)
Study: 16484290
Drug: Iloprost treatment
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost treatment (new protocol)
Study: 16484290
Drug: Iloprost treatment
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost treatment (different dosing schemes)
Study: 12930167
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g.kg body mass per day for 6 days)
Study: 8884833
Drug: Hanks balanced
Normalized name: haNK
DrugBank: CD-16 NK-92 cells (DB17465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hanks balanced salt solution
Study: 21678668
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline solution
Study: 1326734
Drug: High-dose 4'-epi-doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 4'-epi-doxorubicin + cyclophosphamide (800 mg/m2)
Study: 1326734
Drug: High-dose 4'-epi-doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 4'-epi-doxorubicin + cisplatin (60 mg/m2)
Study: 3915883
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg once daily for 15 days
Study: 3915883
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg once daily for 15 days
Study: 31820603
Drug: Qinghou Liyan
Normalized name: Lian Fang
DrugBank: Nelumbo nucifera flower (DB14333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinghou Liyan granules, 5 g each time, 3 times a day, 7 days as one course, 4 courses total
Study: 26945407
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of recombinant human atrial natriuretic peptide (rhANP)
Study: 22197455
Drug: Citrus-based juice
Normalized name: citrus juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus-based juice (300 mL daily for 6 months)
Study: 22197455
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (300 mL daily for 6 months)
Study: 20711715
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump treatment with continuous glucose monitoring
Study: 15199625
Drug: Jieyu pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jieyu pill (JYP)
Study: 9814931
Drug: Low-energy density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy density shock wave therapy (1500 impulses of 0.06 mJ/mm2)
Study: 9814931
Drug: High-energy density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy density shock wave therapy (1500 impulses of 0.28 mJ/mm2)
Study: 28729302
Drug: Vosaroxin 70
Normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosaroxin 70 mg/m2 on days 1 and 4 with decitabine 20 mg/m2 on days 1-5 every 4-6 weeks for up to seven cycles
Study: 28729302
Drug: Vosaroxin 70
Normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosaroxin 70 mg/m2
Study: 15493565
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human follicle-stimulating hormone (rFSH)
Study: 9255748
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone replacement therapy
Study: 8291388
Drug: Titrated sufentanil-midazolam
Normalized name: Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated sufentanil-midazolam infusion
Study: 8291388
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative analgesia with intravenous increments of morphine and midazolam
Study: 2872429
Drug: No tocolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tocolytic treatment (Control)
Study: 30192782
Drug: GR-MD-02 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR-MD-02 (8 mg.kg-1 via IV infusion, biweekly for 16 weeks)
Study: 27100898
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (0.02 g/100 ml blood alcohol concentration)
Study: 22437449
Drug: Lacosamide 50
Normalized name: lacosamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 50 mg single dose
Study: 22437449
Drug: Lacosamide 100
Normalized name: lacosamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 100 mg twice daily
Study: 22437449
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg twice daily
Study: 18367682
Drug: Voice Production
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice Production Therapy (VP)
Study: 18367682
Drug: Voice Production
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice Production Therapy (VP) with self-study
Study: 15726579
Drug: Piribedil (2-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (2-16 mg)
Study: 15726579
Drug: Piribedil (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (16 mg)
Study: 8282330
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (Ang II) infusion
Study: 10517737
Drug: Candesartan (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (inhibitor of Ang II AT1 receptor)
Study: 9052891
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg UID)
Study: 10517737
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg UID)
Study: 7861022
Drug: Zidovudine administered
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine administered to women after the first trimester
Study: 7861022
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy in zidovudine-experienced patients with <50 CD4 cells/mm3
Study: 1873448
Drug: Vitamin A,
Normalized name: Vitamin A, D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A, 25,000 IU; beta-carotene, 50 mg; vitamin E, 800 IU; selenium, 400 micrograms (administered daily)
Study: 1873448
Drug: Placebos (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos (administered daily)
Study: 31915235
Drug: VA-dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA-dual therapy (vonoprazan 20 mg + amoxicillin 750 mg twice/day)
Study: 31915235
Drug: VAC-triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC-triple therapy (vonoprazan 20 mg + amoxicillin 750 mg + clarithromycin 200 mg twice/day)
Study: 17453967
Drug: 4 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 days of G-CSF administration
Study: 17453967
Drug: 6 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 days of G-CSF administration
Study: 18084873
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 mg/day
Study: 3724308
Drug: Flunitrazepam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1.5 mg
Study: 2692145
Drug: Prolonged antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antithrombotic treatment with anticoagulants or antiplatelet drugs (50 mg aspirin + 400 mg dipyridamole daily)
Study: 2692145
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment after 3 months of active therapy
Study: 1096538
Drug: Piracetam 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 4.8 g/day for 3 days
Study: 28770409
Drug: Trigger Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger Point (TP) therapy alone